Successful management of acute renal artery thromboembolism by intra-arterial thrombolytic therapy with recombinant tissue plasminogen activator

Renal Failure

Volumn 25, Issue 4, 2003, Pages 665-670

  Cheng, Ben Chung ^a   Ko, Sheung Fat ^a   Chuang, Feng Rong ^a   Lee, Chih Hsiung ^a   Chen, Jin Bor ^a   Hsu, Kuo Tai ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acute renal artery thromboembolism; Intra arterial thrombolytic therapy; Recombinant tissue plasminogen activator (rt PA)

Indexed keywords

ALTEPLASE; HEPARIN; TECHNETIUM 99M; WARFARIN;

ACUTE RENAL ARTERY THROMBOEMBOLISM; ADULT; ARTICLE; BLOOD CLOT LYSIS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCARDIOGRAM; FOLLOW UP; HEMODYNAMIC MONITORING; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MALE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; THROMBOEMBOLISM; URINALYSIS;

ACUTE DISEASE; ADULT; DISEASE MANAGEMENT; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; RENAL ARTERY OBSTRUCTION; THROMBOEMBOLISM; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0042623700     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120022560     Document Type: Article

References (15)

1. Hoxie, H.J.; Coggin, C.B. Renal infarction. Statistical study of two hundred and five cases and detailed report of an unusual case. Arch. Int. Med. 1940, 65, 587-594.
2. Alex, M.; Davison, J.; Stewart, C.; Jean-Pierre, G.; David, N.S.K.; Eberhard, R.; Christopher, G. W., Eds. Ischemic renal disease. In Oxford Textbook of Clinical Nephrology, 2nd Ed.; Oxford: New York, 1998; Vol. 2, 1679-1688.
3. Domanovits, H.; Paulis, M.; Nikfardjam, M.; Meron, G.; Kurkciyan, I.; Bankier, A.A.; Laggner, A.N. Acute renal infarction. Clinical characteristics of 17 patients. Medicine. 1999, 78 (6), 386-394.
4. John, D.M.; Chadalawada, N.R.; Warren, C.W.; Carl, A.O. Conservative management of renal artery embolus. J. Urol. 1973, 109 (2), 138-143.
5. Hamilton, P.B.; Phillips, R.A.; Hiller, A. Duration of renal ischemia required to produce uremia. Am. J. Physiol. 1948, 109, 517-522.
6. Lessman, R.K.; Johnson, S.F.; Coburn, J.W.; Kaufman, J.J. Renal artery embolism: clinical features and long-term follow-up of 17 cases. Ann Intern. Med. 1978, 89 (4), 477-482.
7. Gasparini, M.; Hofmann, R.; Stoller, M. Renal artery embolism: clinical features and therapeutic options. J. Urol. 1992, 147 (3), 567-572.
8. Verstraete, M.; Collen, D. Pharmacology of thrombolytic drugs. J. Am. Coll. Cardiol. 1986, 8 (6 suppl. B), 33B-40B.
9. Marder, V.J.; Sherry, S. Thrombolytic therapy: current status. N. Engl. J. Med. 1988, 318 (24), 1512-1520;1585-1595.
10. Verstraete, M.; Bounameaux, H.; de Cock, F.; Van de Werf, F.; Collen, D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J. Pharmacol. Exp. Ther. 1985, 235 (2), 506-512.
11. Mügge, A.; Gulba, D.C.; Frei, U.; Wagenbreth, I.; Grote, R.; Daniel, W.G.; Lichtlen, P.R. Renal artery embolism: thrombolysis with recombinant tissue-type plasminogen activator. J. Intern. Med. 1990, 228, 279-286.
12. Collen, D.; Bounameaux, H.; De Cock, F.; Lijnen, H.R.; Verstraete, M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986. 73 (3), 511-517.
13. Krupski, W.C.; Feldman, R.K.; Rapp, J.H. Recombinant human tissue-type plasminogen activator is an effective agent for thrombolysis of peripheral arteries and bypass grafts: preliminary report. J. Vasc. Surg. 1989, 10 (5), 491-500.
14. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 1993, 329 (9), 673-682.
15. Brott, T.G.; Haley, E.C.; Levy, D.E., Jr.; Barsan, W.; Broderick, J.; Sheppard, G.L.; Spilker, J.; Kongable, G.L.; Massey, S.; Reed, R.; Marler, J.R. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992, 23 (5), 632-640.